ATE432470T1 - Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker - Google Patents

Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker

Info

Publication number
ATE432470T1
ATE432470T1 AT01996331T AT01996331T ATE432470T1 AT E432470 T1 ATE432470 T1 AT E432470T1 AT 01996331 T AT01996331 T AT 01996331T AT 01996331 T AT01996331 T AT 01996331T AT E432470 T1 ATE432470 T1 AT E432470T1
Authority
AT
Austria
Prior art keywords
inflammatory bowel
bowel disease
ibd
lactoferrin
endogene
Prior art date
Application number
AT01996331T
Other languages
English (en)
Inventor
James Boone
David Lyerly
Tracy Wilkins
Richard Guerrant
Original Assignee
Techlab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techlab Inc filed Critical Techlab Inc
Application granted granted Critical
Publication of ATE432470T1 publication Critical patent/ATE432470T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01996331T 2000-11-14 2001-11-14 Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker ATE432470T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24828800P 2000-11-14 2000-11-14
PCT/US2001/045301 WO2002039883A2 (en) 2000-11-14 2001-11-14 Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker

Publications (1)

Publication Number Publication Date
ATE432470T1 true ATE432470T1 (de) 2009-06-15

Family

ID=22938469

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996331T ATE432470T1 (de) 2000-11-14 2001-11-14 Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker

Country Status (8)

Country Link
US (3) US7192724B2 (de)
EP (2) EP1340078B1 (de)
AT (1) ATE432470T1 (de)
AU (3) AU2002220029B2 (de)
CA (1) CA2427898C (de)
DE (1) DE60138829D1 (de)
ES (1) ES2325059T3 (de)
WO (1) WO2002039883A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1554580B1 (de) * 2002-10-25 2008-05-14 Techlab, Inc. Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
AU2009314259B2 (en) 2008-11-11 2015-06-11 Nestec S.A. Methods for prediction of inflammatory bowel disease (IBD) using serologic markers
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
ES2509616T3 (es) 2009-06-25 2014-10-17 Nestec S.A. Procedimientos de diagnóstico del síndrome del intestino irritable
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
ES2380664B2 (es) 2010-10-19 2012-09-13 Certest Biotec, S.L. Método y dispositivo para el diagnóstico rápido de enfermedades en muestras fecales.
CN103502815B (zh) 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 检测针对抗-TNFα药物的自身抗体的测定法
US10295535B2 (en) * 2011-04-29 2019-05-21 Techlab, Inc. Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease
US20120276060A1 (en) 2011-04-29 2012-11-01 Techlab, Inc. Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
EP2734543B1 (de) * 2011-07-24 2018-10-03 Carmel-Haifa University Economic Corp. Lactoferrinfragmente und verwendung davon
US20120258477A1 (en) * 2011-07-25 2012-10-11 Northwestern University Fecal neopterin concentration measurement as an indicator of disease activity in inflammatory bowel disease
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
WO2013082288A1 (en) * 2011-11-29 2013-06-06 The Regents Of The University Of California Glucorticoid receptor gene nr3c1 methylation in irritable bowel syndrome and other stress disorders
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
CN103575903B (zh) * 2012-08-07 2016-01-20 中国检验检疫科学研究院 一种人乳铁蛋白夹心elisa检测试剂盒及其应用
RU2504779C1 (ru) * 2012-10-08 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Минздравсоцразвития России Способ оценки эффективности лечения больных язвенным колитом
JP6330032B2 (ja) 2013-06-05 2018-05-23 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法組成物を製造、処理、および梱包するための方法
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP3094973B1 (de) 2013-11-07 2020-07-29 Diagnodus Limited Biomarker
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102066242B1 (ko) 2015-06-09 2020-01-14 리바이오틱스, 인코퍼레이티드 미생물상 복원 치료(mrt) 조성물 및 제조 방법
PL3171174T3 (pl) * 2015-11-20 2018-04-30 Geroa Diagnostics, S.L Laktoferryna do zastosowania w diagnostyce lub prognozowaniu choroby Alzheimera
CN116973572A (zh) * 2023-06-02 2023-10-31 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5124252A (en) * 1989-11-28 1992-06-23 University Of Virginia Alumni Patents Foundation In vitro test for fecal leukocytes
US5552292A (en) 1993-01-18 1996-09-03 Ikagaku Co., Ltd. Method of screening for colorectal cancer
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5681699A (en) 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6174664B1 (en) * 1997-02-05 2001-01-16 University Of Pittsburgh Screening method for inflammatory diseases using neutrophil defensins and lactoferrin
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
AU2002220029B2 (en) 2007-09-06
EP1340078A4 (de) 2006-07-05
AU2007234504A1 (en) 2007-12-06
EP2071332A1 (de) 2009-06-17
US20040033537A1 (en) 2004-02-19
WO2002039883A2 (en) 2002-05-23
EP1340078B1 (de) 2009-05-27
CA2427898C (en) 2017-08-15
WO2002039883A3 (en) 2002-08-08
US7560240B2 (en) 2009-07-14
US20090253155A1 (en) 2009-10-08
US20020168698A1 (en) 2002-11-14
US7192724B2 (en) 2007-03-20
DE60138829D1 (de) 2009-07-09
ES2325059T3 (es) 2009-08-25
EP1340078A2 (de) 2003-09-03
AU2007234504B2 (en) 2010-11-18
CA2427898A1 (en) 2002-05-23
US7892762B2 (en) 2011-02-22
AU2002902A (en) 2002-05-27

Similar Documents

Publication Publication Date Title
ATE432470T1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
ATE532070T1 (de) Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
ATE437371T1 (de) Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
DE69837709D1 (de) Vorrichtung und verfahren zur bestimmung des analytpegels
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
ATE319093T1 (de) Verfahren zur diagnose von leberkrankheit unter verwendung von biochemischen merkmalen
NO20052992L (no) Markorproteiner for diagnostisering av leversykdom og fremgangsmate for diagnostisering av leversykdom.
ATE539675T1 (de) System und verfahren zur bestimmung einer analytenkonzentration mit einer hämatokrit- korrektur
ATE438737T1 (de) Verfahren für den nachweis von erkrankungen
ATE251222T1 (de) Verfahren zur bestimung von ki-ras mutationen und dieses leistender testsatz
ATE488765T1 (de) Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung
ATE278186T1 (de) Elektrochemischer sensor zur bestimmung der blutgerinnung, ein entsprechendes blutgerinnungsmesssystem sowie ein verfahren zur bestimmung der blutgerinnung
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
DE60133510D1 (de) Automatisches Verfahren zur quantitativen Bestimmung und Überwachung von exogenem Hämoglobin in Vollblut, Blutplasma und Blutserum
DE60318435D1 (de) Universeller biosensor und verfahren zur verwendung
ATE434760T1 (de) Blutzellen-detektor, blutanalysegerät und blutanalyseverfahren unter verwendung des detektors
DE602004020372D1 (de) Verfahren zur probenvorbehandlung sowie immunologisches testverfahren unter verwendung davon
DE69531505D1 (de) Verfahren zur zellerkennung
ATE470154T1 (de) Verfahren zur bewertung von insulinresistenz
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
DE60225168D1 (de) Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür
DE60322240D1 (de) Katzenpankreas-lipase-zusammensetzung und verfahren zur herstellung und verwendung einer solchen zusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties